

---

## AlzeCure Pharma (Q3 Review) - Clinical phase IIa study in focus

Redeye returns with an update following AlzeCure's Q3 earnings release, which aligned with our expectations. With a reinforced cash position, AlzeCure now prepares to initiate a phase IIa study with NeuroRestore ACD865 in patients with Alzheimer's disease in 2026. Simultaneously, the company continues its business development efforts regarding all four of its candidates.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**AlzeCure Pharma (Q3 Review) - Clinical phase IIa study in focus**